US 12,433,849 B2
Particles comprising a therapeutic or diagnostic agent and suspensions and methods of use thereof
Chase Coffman, Newton, MA (US); Lyndon Fitzgerald Charles, Jr., Medford, MA (US); Paul Brown, Boston, MA (US); Daniel Benjamin Dadon, East Boston, MA (US); Lisa Liu, Somerville, MA (US); Sadiqua Shadbar, Allston, MA (US); and Chaitanya Sudrik, Stoneham, MA (US)
Assigned to Elektrofi, Inc., Boston, MA (US)
Filed by Elektrofi, Inc., Boston, MA (US)
Filed on Feb. 21, 2025, as Appl. No. 19/060,326.
Application 19/060,326 is a continuation of application No. 18/816,200, filed on Aug. 27, 2024, granted, now 12,263,253.
Application 18/816,200 is a continuation of application No. 17/058,339, granted, now 12,115,262, issued on Oct. 15, 2024, previously published as PCT/US2019/033875, filed on May 24, 2019.
Claims priority of provisional application 62/676,169, filed on May 24, 2018.
Prior Publication US 2025/0228790 A1, Jul. 17, 2025
Int. Cl. A61K 9/51 (2006.01); A61K 31/167 (2006.01); A61K 45/06 (2006.01); A61K 47/02 (2006.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01)
CPC A61K 9/5192 (2013.01) [A61K 31/167 (2013.01); A61K 45/06 (2013.01); A61K 47/02 (2013.01); A61K 47/14 (2013.01); A61K 47/186 (2013.01); A61K 47/26 (2013.01)] 20 Claims
 
1. A composition comprising dehydrated particles, wherein a plurality of the particles comprise a protein,
wherein the protein has 0.5 to 1.0 activity per unit and is present in the plurality of the particles in an amount of from 50 wt % to 100 wt %, and
wherein the plurality of the particles: are solid particles, have less than 10% water content, have less than 5% aggregation of the protein, and are suspended in a non-aqueous liquid.